Cannabis Contaminant Control

A practical quality hub covering chemical, elemental and process-related contaminants in cannabis materials and products.

1 min read · Last reviewed: July 2026 · European Cannabis Institute Editorial Team

Explore this Phase 3 topic

This hub connects focused technical articles with ECI's existing knowledge, quality and professional-development content.

Supporting article

Residual Solvent Testing

Risk-based solvent control from extraction through finished-product release.

Read article →

Supporting article

Heavy Metals Testing

How cultivation, processing and packaging can affect elemental impurity risk.

Read article →

References

EU GMP Annex 1 (2022) — Contamination Control Strategy
Ph. Eur. 5.1.4 — Microbiological Quality of Non-Sterile Preparations
ICH Q9(R1) — Quality Risk Management

Confirm the current effective version and national applicability before operational, regulatory or clinical use.

Use the knowledge in practice

Apply these principles through ECI training, assessment tools and specialist consultancy support.

Explore courses Contact ECI

Frequently asked questions

What is the main quality objective for cannabis contaminant control?

The objective is to define and maintain controls that ensure identity, consistency, safety and fitness for the intended use.

Which regulatory framework applies?

The applicable framework depends on jurisdiction, intended use, product classification and lifecycle stage. EU GMP, pharmacopoeial and product-specific requirements may all be relevant.

Is finished-product testing sufficient?

No. Testing is only one element of assurance. Supplier controls, process understanding, qualification, in-process monitoring and data governance are also required.

How should specifications be set?

Specifications should be scientifically justified using process capability, safety considerations, stability data, pharmacopoeial requirements and the intended clinical or technical use.

Why is trending important?

Trending can reveal gradual drift, supplier changes or method deterioration before individual results breach an acceptance limit.